FIRST AMENDING AGREEMENTShare Purchase Agreement • November 10th, 2021 • Liminal BioSciences Inc. • Pharmaceutical preparations
First Amending Agreement (the "Amending Agreement") dated November 10, 2021 between Liminal BioSciences Inc. ("Purchaser") , Fairhaven Pharmaceuticals Inc. (the "Corporation"), The Royal Institution for the Advancement of Learning/McGill University (“McGill”), AMORCHEM, LIMITED PARTNERSHIP ("AmorChem LP"), Genesys Ventures III LP ("Genesys") and MSBI Valorisation Inc. (“MSBI”, collectively, with McGill, AmorChem LP and Genesys, the "Sellers") and each of Elizabeth Douville and Jamie Stiff solely in their capacity as Agents of the Sellers (as defined in the Share Purchase Agreement)
